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TITLE: Robust association between vascular habitats and patient prognosis in Glioblastoma: 
an international multicenter study 
 
ABSTRACT: 
Background: Glioblastoma is the most aggressive primary brain tumor characterized by a 
heterogeneous and abnormal vascularity. Vascular habitats within the enhanced tumor and 
the tumoral edema can be distinguished: High Angiogenic Tumor (HAT), Low Angiogenic 
Tumor (LAT), Infiltrated Peripheral Edema (IPE), and Vasogenic Peripheral Edema (VPE).  
Purpose: To validate the association between hemodynamic markers from vascular habitats 
and overall survival (OS) in glioblastoma patients and the inter-center variability of MRI 
acquisition protocols. 
Study type: multicenter retrospective study. 
Population: 184 glioblastoma patients from seven European centers participating in the 
NCT03439332 clinical study. 
Field Strength/Sequence: 1.5 (for 54 patients) or 3.0T (for 130 patients); Pre-gadolinium 
and post-gadolinium-based contrast agent-enhanced T1-weighted MRI, T2- and FLAIR T2-
weighted and DSC T2* perfusion. 
Assessment: Preoperative MRIs were analyzed to establish the association between the 
maximum relative Cerebral Blood Volume (rCBVmax) at the HAT, LAT, IPE and VPE 
habitats with OS. Moreover, the stratification capabilities of the hemodynamic markers to 
divide patients into long and short survivors were tested. The independence of the markers 
from the center acquisition was also assessed. 
Statistical Tests: Uniparametric Cox regression. Kaplan-Meier test. Mann-Whitney test 
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Results: The rCBVmax derived from the HAT, LAT and IPE habitats were significantly 
associated with patient OS (p<0.05; HR:1.05, 1.11, 1.28 respectively). Moreover, these 
markers can stratify patients into short and long survivors (p<0.05). The Mann-Whitney test 
found no significant differences among most of the centers, and no significant differences 
were observed in the Cox regression and Kaplan-Meier analyses among each of the 
participating centers. 
Data Conclusion: The rCBVmax calculated in HAT, LAT and IPE habitats is a clinically 
relevant prognostic biomarker for glioblastoma patients in the pre-treatment stage. This study 
demonstrates the relevance of the HTS habitats to assess the GBM vascular heterogeneity 
and their association with patient prognosis independently of the inter-center variability.  
 
KEYWORDS: Glioblastoma; vascularity; perfusion DSC; overall survival; multicenter 
study 
 
LIST OF ABBREVIATIONS: 
• DSC: Dynamic Susceptibility Contrast 
• GBM: Glioblastoma 
• HAT: High Angiogenic Tumor 
• IPE: Infiltrated Peripheral Edema 
• LAT: Low Angiogenic Tumor 
• MR: Magnetic Resonance 
• MRI: Magnetic Resonance Imaging 
• OS: Overall Survival 
• rCBVmax: maximum relative Cerebral Blood Volume 
3 
 
• TE: Echo Time 
• TR: Repetition Time 
• ROI: Region of Interest 






Glioblastoma (GBM) is the most aggressive malignant primary brain tumor in adults and 
results in a median survival rate of 12-15 months (1, 2). It still carries a poor prognosis despite 
aggressive treatment, which includes tumor resection followed by chemo-radiotherapy (2-4). 
One of the main factors thought to be responsible for GBM’s aggressiveness is its vascular 
heterogeneity (4, 5), mainly defined by strong angiogenesis, which supplies the GBM’s 
metabolic needs and accounts for its rapid progress (6, 7). The vascular profile of the tumor 
is strongly associated with the molecular characteristics of the lesion (7), which means that 
the vascular conditions of the early tumor stages and its environment are both associated with 
GBM progress (6). 
The negative association between patient survival rates and vascular features extracted from 
perfusion MRI has been widely analyzed in the literature (4, 8, 9). In these studies, perfusion 
indices such as relative Cerebral Blood Volume (rCBV) or capillary heterogeneity were 
found to have prognostic capabilities. The methodologies employed to assess these perfusion 
indices range from manually defined ROIs, which introduce high uncertainty and lack 
repeatability, to more up-to-date techniques based on artificial intelligence methods able to 
analyze tumoral heterogeneity (10-15). 
In 2018, Juan-Albarracín et al. (16) proposed the HTS methodology (freely accessible at 
ONCOhabitats site: https://www.oncohabitats.upv.es) to characterize GBM’s vascular 
heterogeneity by means of delineating the vascular habitats. This technique, known as the 
Hemodynamic Tissue Signature (HTS), defines four habitats within the lesion with different 
hemodynamic behavior: The High Angiogenic Tumor (HAT) habitat, Low Angiogenic 
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Tumor (LAT) habitat, potentially Infiltrated Peripheral Edema (IPE) and the Vasogenic 
Peripheral Edema (VPE). This study found a significant correlation between overall survival 
(OS) and HTS markers in the high and low angiogenic habitats (16).  In 2018, Fuster et al. 
demonstrated the ability of these imaging markers to improve the prognosis of conventional 
models based on clinical, morphological and demographic features (17), although both 
studies were performed on a limited number of patients from a single hospital. 
Although both researchers and clinicians are increasingly demanding imaging markers for 
decision making (18), to validate them in clinical practice, two translational gaps have to be 
overcome (O’Connor et al (19)): the first is related to using preclinical or clinical datasets 
from a single or only a few expert centers. The second requires that multiple centers be 
involved in the study, together with the biological validation of the biomarkers. Although 
previous studies (16, 17) overcame the first translational gap, to validate the vascular markers 
from the HTS habitats, an extended multicenter study is needed. 
This paper presents the preliminary results of the international retrospective multicenter 
study NCT03439332, registered at ClinicalTrial.gov 
(https://clinicaltrials.gov/ct2/show/NCT03439332). The study focuses on the validation of 
the association between GBM vascular heterogeneity described by the HTS habitats and the 
patient OS in a large heterogeneous international cohort and includes imaging and clinical 





MATERIALS AND METHODS 
Patient selection 
The following seven European clinical centers participated in the study: the Hospital 
Universitario de La Ribera, Alzira, Spain; Hospital de Manises, Manises, Spain; Hospital 
Clinic, Barcelona, Spain; Hospital Universitario Vall d’Hebron, Barcelona, Spain; Azienda 
Ospedaliero-Universitaria di Parma, Parma, Italy; Centre Hospitalier Universitaire de Liège, 
Liège, Belgium and the Oslo University Hospital, Oslo, Norway. A Material Transfer 
Agreement (MTA) was approved by all the participating centers and an acceptance report 
was issued by the Ethical Committee of each center. The managing institution review board 
also approved this retrospective study and the requirement for patient-informed consent was 
waived. 
The inclusion criteria for patients participating in the study were: (a) adult patients (age > 18 
y.o.) with histopathological confirmation of GBM diagnosed between January 1, 2012 and 
January 1, 2018; (b) access to the preoperative MRI studies, including: pre- and post-
gadolinium T1-weighted, T2-weighted, FLuid-Attenuated Inversion Recovery (FLAIR) and 
Dynamic Susceptibility Contrast (DSC) T2*-weighted perfusion sequences; and (c) patients 
who underwent standard Stupp treatment (20) with a minimum survival of 30 days.  
 
Magnetic Resonance Imaging 
Standard-of-care MR examinations were obtained at 1.5-T or 3-T scanners.  Pre-gadolinium 
and post-gadolinium-based contrast agent-enhanced T1-weighted MRI, as well as T2-
weighted, FLAIR T2-weighted and DSC T2* perfusion MRI sequences were collected from 
each center participating in the study. Supporting Information Table S1 summarizes the MRI 
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acquisition protocols grouped by center, including the Magnetic Field Strength, Repetition 
Time, Echo Time, matrix size, slice thickness, Field of View and the number of temporal 
acquisitions of the perfusion MR sequence. 
 
GBM vascular heterogeneity assessment through HTS habitats 
The HTS methodology from the ONCOhabitats platform was used to analyze the MRI 
studies. This methodology is composed of four stages: (1) Preprocessing, which includes 
correction of common MRI artifacts such as magnetic field in homogeneities and noise, 
multi-modal registration, brain extraction and motion correction; (2) GBM tissue 
segmentation, which implements a state-of-the-art deep learning 3D Convolutional Neural 
Network (CNN) that segments the enhancing tumor, edema and necrosis tissues; (3) DSC 
Perfusion Quantification, which calculates the hemodynamic maps derived from the DSC 
perfusion sequence (relative Cerebral Blood Volume (rCBV), relative Cerebral Blood Flow 
(rCBF), Mean Transit Time (MTT) and K2 permeability; and (4) Hemodynamic Tissue 
Signature map, in which an automated unsupervised segmentation algorithm is employed to 
detect four habitats with different hemodynamic behavior types: the High Angiogenic Tumor 
(HAT) habitat, Low Angiogenic Tumor (LAT) habitat, potentially Infiltrated Peripheral 
Edema (IPE) and the Vasogenic Peripheral Edema (VPE) (see Figure 1). Following (21), we 
define the HTS marker as the maximum rCBV (rCBVmax) computed as the 95th percentile of 
the rCBV distribution within a habitat. The GBM vascular heterogeneity of all the patients is 
thus described by four HTS markers, one for each habitat. 
 
Association between patient OS and HTS markers (whole cohort) 
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Cox proportional hazard regression analysis was used to measure the associations between 
patient OS and HTS markers. The Proportional Hazard Ratios (HR) with a 95% confidence 
interval was reported, as well as the associated p-values corrected for multiple hypothesis 
testing by the False Discovery Rate (FDR) method (α-level: .05).  
Kaplan-Meier analyses were performed to study the stratification abilities of the HTS 
markers to divide the population into short and long-term survivals. The optimum cut-off 
threshold for each perfusion index and habitat was determined by the C-index method.  The 
C-Indexes for the final cut-off thresholds were also reported. The log-rank test was used to 
determine any statistical differences between the estimated survival functions of the groups 
divided by the HTS markers. 
 
Association between patient OS and HTS markers per center  
The similarities between the HTS marker distributions among the clinical centers with 
different MRI protocols were evaluated to determine the degree of agreement in describing 
tumor vascular heterogeneity. To do so we conducted a pair-wise Mann-Whitney U test to 
compare the distributions of the HTS markers of each center, considering that p-values higher 
than 0.05 implied no significant differences between the HTS markers calculated for these 
centers. 
As in the analyses for the whole cohort, Cox regression analyses were conducted to assess 
whether the association between patient OS and HTS markers differed among the centers. 
Kaplan-Meier analyses were performed after dividing the population of each center using the 
cut-offs for each HTS marker previously calculated for the whole cohort. 





From the initial cohort, consisting of 196 GBM patients, four cases were excluded due to 
HTS processing errors; five cases were excluded due to noise or MR artifacts that precluded 
DSC quantification (gamma variate R2 goodness of fit < 0.95); one case was excluded due to 
inability to differentiate between tumor vascularity and reactive meningeal enhancement; and 
two cases were excluded due to defective perfusion images. 
The study finally included 184 patients. Supporting Information Table S2 gives the patients 
from each center. Those who were still alive during the study were considered as censored 
observations, the date of censorship being the last date of contact with the patient or, if this 
information was not available, the date of the last MRI exam. Table 1 summarizes the most 
important demographic and clinical characteristics of the studied population. 
 
Association between patient OS and HTS markers (whole cohort) 
Table 2 shows the Cox proportional hazard analysis between HTS markers and patient OS. 
A significant correlation was found between CBVmax at HAT, LAT and IPE habitats (p<0.05, 
FDR<0.05) and patient OS. Negative associations were also found between patient OS and 
the rCBVmax in these habitats. 
The Kaplan-Meier results are summarized in Table 3, including estimated optimal cut-off 
thresholds, number of patients per group, estimated C-index, median OS calculated per 
group, and log-rank test results (p-values). Significant OS differences between low and high 
rCBVmax were found in HAT, LAT and IPE. Those with low rCBVmax in these habitats 
presented a higher median survival rate.  
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The Kaplan-Meier curves for the populations divided by high and low rCBVmax in the 
vascular habitats are shown in Figure 2. The ability of the HTS markers to stratify patients 
into short and long-term survivors can be seen to coincide with the vascularity within the 
habitats. 
 
Association between patient OS and vascular habitats per center  
No significant differences were found between the rCBVmax values of the habitats in most of 
the centers (P>0.05) (see Supporting Information Tables S3.1, S3.2 and S3.3). This can be 
seen in the box-whisker diagram in Figure 3, which shows how the rCBVmax intervals for 
each hospital overlap. 
Table S4 shows the results of the Cox regression analysis, broken down by hospital, of the 
HTS markers that yielded a significant association with OS (Table 2). Figure 4 contains a 
graph of the results, showing an unambiguous overlap between confidence intervals for most 
of the centers, suggesting no significant differences among them in calculating HTS markers. 
The results of the association of HTS markers and OS per hospital are consistent with those 
obtained for the whole cohort. 
The Kaplan-Meier plot shows the stratification of the population per hospital in high and low 
vascular GBMs, using the optimal C-index thresholds shown in Figure 5. For the sake of 
clarity, this Figure only gives the results of the HAT marker (i.e. the HTS marker in the HAT 
habitat), as this showed the clearest differences between the populations. Supporting 





This paper gives the complete results of the multicenter validation focused on the first 
hypothesis defined in the NCT03439332 clinical study. Using data from seven European 
centers, significant negative associations were found between patient OS and the HTS 
markers in the HAT, LAT and IPE habitats. These results agree with a previous study (16) 
in which significantly longer survival rates were found for patients with lower rCBVmax.  
Overcoming the variability in calculating imaging markers is not easy. Other authors have 
pointed out the uncertain or low reproducibility of some MRI markers, especially across 
centers (18, 19, 22, 23). A manual definition of ROIs and the interpretation of images by 
several experts may be other sources of variability, making it difficult to validate new 
imaging markers (22). 
Although the current study involved a cohort with large variations in terms of patient 
demographics, as well as image acquisition protocols (see Tables 1 and Supporting 
Information Table S1), we did not find any relevant differences among the distributions of 
the HTS markers calculated from MRIs from different centers. Only one center, the Clinic 
de Barcelona, was found to have significant differences with the HAT markers from other 
centers. These results suggest that the proposed method is robust against inter-center 
variability in calculating vascular habitat HTS markers. Furthermore, the results of the Cox 
and Kaplan-Meier analysis per center show a robust association between patient OS and the 
HTS markers, regardless of the center of origin. The proposed thresholds were also effective 
in stratifying patients from different centers into long and short-term survivors according to 
their vascular profile.  
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Having demonstrated the influence of early-stage vascularity on the prognosis of GBM 
patients, this important factor may now be considered in any clinical study that includes 
population randomization. Until now, this variable has not been considered in clinical studies, 
mainly due to the lack of a robust and valid method of processing MRIs acquired under 
different conditions (i.e. different MRI protocols). The authors consider that the HTS method 
will help to overcome the current limitations and improve patient recruitment and 
randomization by initiating a route map to avoid the second translational gap cited above 
(18).  
The proposed method segments the enhancing tumor into two habitats with different vascular 
profiles (i.e. HAT and LAT). Since HAT is the most vascular region in the tumor, the HAT 
rCBVmax is quite similar to rCBVmax in the whole enhancing tumor. In this regard, the 
correlation between high perfusion values in the HAT habitat and short-term OS is 
compatible with previous studies (8, 24, 25) that found a relationship between the perfusion 
parameters in the enhancing tumor region and the patient’s survival rates. 
We also found that the LAT habitat in the enhancing tumor has a strong association with OS 
and high stratification abilities. Sawlani RN et al. in (26) suggested the potential of the mean 
rCBV of the enhancing tumor as a predictive marker. The mean rCBV values obtained here 
for the whole tumor are comparable with the rCBVmax in the LAT habitat. In 2005, 
Hambardzumyan & Bergers defined different GBM niches based on different cell 
constituents and the functional status of the vasculature (27). They distinguished between the 
perivascular niche, with vigorous and abnormal angiogenesis leading to a heterogeneous 
organization of blood vessels, and the hypoxic niche, with lower blood volume and flow 
values. Even though these regions could be consistent with the HAT and LAT habitats 
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proposed here, we have gone a step further and identified a new important region within the 
tumor which provides automatic reproducibility in calculating valuable prognostic imaging 
markers. 
One of the most important of the present findings is the correlation found between long-term 
OS and low rCBVmax in the IPE habitat. Edematous tissue has received much less attention 
than the active tumor in previous studies, although there is evidence that the vascularity in 
this area can influence tumor evolution and patient prognosis (28). In 2014, Jain R et al. (8) 
showed that the edema rCBV generally provided relevant prognostic information. Artziet al. 
(28) described differences between the vasogenic and peripheral edema at the metabolic and 
vascular levels (28), while we found the HTS method can automatically delineate the 
infiltrated edema area, i.e. IPE. The clinical implications of this ability are given by the strong 
association between the IPE marker, patient prognosis, and the ability to stratify patients into 
long and short-term survivors, opening up new pre-surgical treatment options. 
Since the influence of the molecular markers on patient prognosis has been demonstrated (1, 
29), it may be of interest to add them as cofactors in survival models. The present multicenter 
study focused on the robustness of the HTS markers in dealing with images from multiple 
centers. In future studies we hope to analyze the possible association between molecular and 
imaging markers and their prognostic possibilities.  
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Table 1: Demographic and clinical data of the 184 patients included in the study. 
 










AO Parmae CH Liègef Oslo UHg Total 
GENDER (F/M)          




        
- Mean 49  65 56 60 61 58 63 60 
- Range [24,67] [39,79] [35,74] [30,81] [35,76] [32,77] [40,81] [24,81] 
SURVIVAL 
(months) 
        
- Mean 14.6 14.4 10.3 15.2 11.7 15.3 15.4 13.7 
- Median 9.1 12.8 9.6 13.0 12.9 14.5 12.6 12.6 
- Range [3.4,52.6] [3.4,38.4] [1.3,26.9] [4.1,40.0] [1.1,30.7] [2.5,41.0] [3.0,36.9] [1.1,52.6] 
RESECTION  
(# of patients) 
- Total 3  3 0 12 19 22 11 70 
- Sub-total 1  4 10 10 15 6 21 67 
- Biopsy 1 7 6 11 2 5 0  32 
- Unknown 2  0 9 0 4 0 0 15 
TUMOR LOCATION  
(# of patients) 
-Frontal 2  4  7 10  18  11  12  64 
-Parietal 2  0  5 7  4  9  3  30 
-Temporal 3  7  11 13  12  9 14  69 
-Occipital 0  2  1 2  2  0  1  8 
-Other /Unknown 0  1  1 1  4  4  2  13 
IDH1         
-Mutated 2  0  4  0  0  0 1 6 
-Wild type 2  0  4  32 30  34 31 99 
-Unknown 3  14  17  1  10 0 1 79 
Hospital de la Riberaa; Hospital de Manisesb; Clinic de Barcelonac; Hospital Vall d’Hebrond; Azienda 
Ospedaliero-Universitaria di Parmae; Centre Hospitalier Universitaire de Liègef; Oslo University Hospitalg    
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Table 2: Cox regression analysis for rCBVmax of the vascular habitats to predict overall patient 









HAT 1.05 [1.01, 1.09] 0.0115* 0.0174* 
LAT 1.11 [1.02, 1.20] 0.0131* 0.0174* 
IPE 1.28 [1.05, 1.55] 0.0122* 0.0174* 
VPE 1.19 [0.89, 1.60] 0.2502 0.2502 
HTS: Hemodynamic Tissue Signature; HAT: High Angiogenic Tumor; LAT: Low Angiogenic Tumor; IPE: Infiltrated 




Table 3: Kaplan Meier and Log Rank test results for rCBVmax in HAT, LAT, IPE and VPE to stratify 

















rCBVmax  Low   High  Low   High  
HAT 11.06 [97, 87] 0.606 [14.3, 11.3] 0.0014* 
LAT 5.31 [91, 93] 0.605 [13.9, 11.3] 0.0085* 
IPE 1.92 [59 125] 0.634 [14.3, 11.4] 0.0101* 
VPE 1.67 [100, 84] 0.599 [13.8, 11.2] 0.1356 
HTS: Hemodynamic Tissue Signature; rCBVmax: Maximum relative Cerebral Blood Volume; HAT: High Angiogenic 
Tumor; LAT: Low Angiogenic Tumor; IPE: Infiltrated Peripheral Edema; VPE: Vasogenic Peripheral Edema; AUC: Area 







Figure 1: Hemodynamic Tissue Signature (HTS) methodology: (1): Preprocessing; (2): 
Segmentation; (3): DSC Perfusion Quantification; (4): Hemodynamic Tissue Signature. High 
Angiogenic Tumor (HAT), Low Angiogenic Tumor (LAT), Infiltrated Peripheral Edema 
(IPE), and Vasogenic Peripheral Edema (VPE). 
 
Figure 2: Kaplan-Meier estimated survival functions for the populations stratified into 
groups according to high or low rCBVmax in HAT (left), LAT (center) and IPE (right) 
habitats. 
 
Figure 3: Boxplot of the HTS markers (rCBVmax at HAT, LAT, IPE and VPE) of 
glioblastoma patients of each participating center. 
 
Figure 4: Plot with the Hazard Ratios (HR) and 95% Confidence Intervals (CIs) to study the 
association between the overall survival and the HTS markers at HAT, LAT and IPE for each 
center. The continuous black line and the grey band correspond respectively to the value of 
HR and CIs obtained by performing the Cox analysis with data from all centers and for each 
HTS marker. The black markers are those of the HR obtained by performing the Cox analysis 
with the data from each center and each HTS marker. 
 
Figure 5: Kaplan-Meier estimated survival functions for the populations of each center 
stratified into groups according to high or low rCBVmax in HAT, divided by the threshold 
calculated with the data of all the center (cut off threshold of 11.6).  
 
